Diasorin's organic sales grew 8% in the third quarter (10% on a reported basis), outpacing PitchBook-compiled consensus estimates. This marks a substantial acceleration from first-half performance, prompting management to confirm full-year guidance for 5%-6% constant-currency sales growth.
The innovative and flexible syndromic testing platform, Liaison Plex, will enable Diasorin to gain market share in the syndromic testing market.
Diasorin has been slow to enter the molecular point-of-care market, which could limit its ability to capture market share.
Metric | DIA | ABT | BIO |
|---|---|---|---|
Price/Earnings (Normalized) | 29.76 | 19.93 | 39.92 |
Price/Book Value | 2.97 | 3.64 | 1.31 |
Price/Sales | 4.09 | 3.88 | 3.85 |
Price/Cash Flow | 19.86 | 17.94 | 76.38 |
Metric | DIA | ABT | BIO |
|---|---|---|---|
Quick Ratio | 0.81 | 1.00 | 2.15 |
Current Ratio | 1.79 | 1.45 | 3.18 |
Interest Coverage | 7.37 | 7.30 | 26.33 |
Metric | DIA | ABT | BIO |
|---|---|---|---|
Return on Assets (Normalized) | 7.09% | 9.44% | 2.55% |
Return on Equity (Normalized) | 13.48% | 18.30% | 3.63% |
Return on Invested Capital (Normalized) | 9.39% | 12.90% | 2.73% |
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Thermo Fisher Scientific Inc TMO | LOCK|J@c!tdtq | LOCK|yn@ | $259B | |||
| Danaher Corp DHR | LOCK|!vmB<m#$ | LOCK|KjB | $163B | |||
| IDEXX Laboratories Inc IDXX | LOCK|^<H?Jg^ | LOCK|M% | $55B | |||
| Agilent Technologies Inc A | LOCK|HGjtk^q | LOCK|?> | $49B | |||
| Waters Corp WAT | LOCK|^>SB#< | LOCK|T> | $45B | |||
| IQVIA Holdings Inc IQV | LOCK|N#bj<TD | LOCK|Bq!&G | $45B | |||
| Mettler-Toledo International Inc MTD | LOCK|!DxP%tM | LOCK|tjZ%t | $34B | |||
| Illumina Inc ILMN | LOCK|H^k^^< | LOCK|TqX# | $32B | |||
| Labcorp Holdings Inc LH | LOCK|?DTr%v< | LOCK|PyQ< | $30B | |||
| Quest Diagnostics Inc DGX | LOCK|SbD$z# | LOCK|bNG! | $29B |
United States